AprilBio: Shares Down 55.7% Over a Year as Revenue Fades and Losses Persist

Thesis

The data supports a picture of a lumpy, development-stage business. Revenue was ₩27.5B in 2024 with an operating profit of ₩16.9B, but fell 92.1% in 2025 to ₩2.2B and turned to a loss. That pattern suggests earnings depend on irregular income rather than steady sales, though the data does not say what drove each year.

The balance sheet is light on debt, with liabilities at 1.5% of equity. Cash of ₩7.4B against a trailing free cash flow of -₩4.7B is a point to watch. The data does not give a cash runway or funding plans.

Trading signals are weak. Foreign investors and institutions were net sellers over 20 days (-₩7.2B and -₩6.3B), while retail investors were net buyers (+₩13.3B). Foreign ownership fell from 12.7% to 9.4% in 60 days. Short balance is low at 0.1%.

Business overview

AprilBio is a biotech and pharma company listed on KOSDAQ since 2022-07-28 and founded in 2013. It has 27,558,782 listed shares and a market cap of about ₩351.4B. Revenue history is uneven: ₩200M in 2022, none in 2023, ₩27.5B in 2024 and ₩2.2B in 2025. A news item from 2026-10-22 (Money Today) reports a three-way agreement among Oncocross, April Bio and OmicsAI for joint new drug development; the data gives no financial terms.

Financial analysis

These figures come from filed financial statements. Trailing revenue to H1 2026 was ₩725M, with an operating loss of ₩9.6B and a net loss of ₩9.0B. Operating margin was -1,324.1% and net margin -1,242.5%. ROE was -9.6%.

For 2025, revenue was ₩2.2B, operating loss ₩7.3B and net loss ₩9.7B, with ROE of -10.4%. In 2024, net income was ₩20.0B and ROE 26.9%. 2023 showed a net loss of ₩14.1B.

Cash was ₩7.4B and borrowings ₩769M. Trailing free cash flow was -₩4.7B.

Valuation

Price-to-earnings and EV/EBITDA are not available because earnings are negative. Price-to-book is 3.6 versus 15.7 at the end of 2025, 4.9 at the end of 2024 and 3.5 at the end of 2022. Price-to-sales is 484.4, reflecting very small revenue. Enterprise value is about ₩271.4B. No dividend is paid.

Listed peers show P/B of 2.5 (Celltrion) to 29.1 (Alteogen), with P/E from 15.0 to 81.0, but they are much larger and profitable, so comparison is limited.

The valuation model (5-year discounted cash flow at an 8.8% rate) gives a model estimate based on the assumptions shown of ₩3,244 per share, with bear ₩3,261 and bull ₩3,223. The narrow and oddly ordered range suggests low sensitivity to the assumptions. The estimate is well below the ₩12,750 share price. It is not a target or a reason to act.

Catalysts

• The 2026-10-23 filings on an amended change of largest shareholder and a 5%+ holding report point to shifts in ownership that may matter for control.
• The Extraordinary Shareholders' Meeting results and the stock purchase option grant, both on 2026-09-22, along with an independent director appointment report, show governance and incentive changes.
• The Oncocross, April Bio and OmicsAI joint drug development agreement reported on 2026-10-22 could matter if it leads to disclosed terms.
• An investor relations event on 2026-10-07 and insider shareholding reports in September show ongoing company and insider activity.

Risks

• Revenue is volatile, falling 92.1% in 2025 and reaching only ₩725M over the trailing twelve months, so earnings are not predictable.
• Operating losses of ₩9.6B and negative free cash flow of -₩4.7B compare with cash of ₩7.4B, which may require new funding.
• The share price is near its 52-week low and down 48.6% in three months, showing heavy selling pressure.
• Foreign and institutional investors are net sellers, and foreign ownership fell by 3.3 percentage points in 60 days.
• The model estimate of ₩3,244 per share is far below the market price, so the valuation relies on expectations the filed numbers do not show.

Closing view

The data shows a company whose 2024 profit proved a one-off against weak results since then, with trailing revenue almost nil, ongoing losses and thin cash, offset by very low debt. The share price has fallen sharply but remains well above the model estimate, and recent filings point to ownership and governance changes whose effects are not yet clear. The partnership news is early and lacks financial detail, so investors should weigh funding needs and revenue visibility, which the data does not resolve.

Model estimate of fair value

Bear

₩3,261

-74%

Base

₩3,244

-74%

Bull

₩3,223

-74%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 8.8%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• Amended: Change of largest shareholderOct 23, 2026
• 5%+ holding reportOct 23, 2026
• Investor relations (IR) eventOct 7, 2026
• 5%+ holding reportSep 28, 2026
• Results of Extraordinary Shareholders' MeetingSep 22, 2026
• Notice on Grant of Stock Purchase OptionsSep 22, 2026
• Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsSep 22, 2026
• Insider shareholding reportSep 18, 2026
• Insider shareholding reportSep 17, 2026
• 5%+ holding reportSep 9, 2026
• Amended: Shareholders' meeting calledSep 7, 2026
• Notice of shareholders' meetingSep 7, 2026
• Oncocross Signs Three-Way Agreement with April Bio and OmicsAI for Joint New Drug DevelopmentOct 22, 2026
• Daily prices up to 2026-10-23
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 24, 2026InitiationStart of coverage (reader request)AprilBio: Shares Down 55.7% Over a Year as Revenue Fades and Losses Persist